Alzheimer’s Treatment Receives FDA Approval

On July 2, the U.S. Food and Drug Administration (FDA) granted traditional approval to donanemab (Eli Lilly), sold under the brand name Kisunla (kih-SUHN-lah), for the treatment of people living with early symptomatic Alzheimer’s disease, which includes mild cognitive impairment and the mild dementia stage of Alzheimer’s disease, with confirmed amyloid plaques. This is the third FDA approval granted for an Alzheimer’s treatment that changes the underlying course of the disease.

• Share
• Discuss
• July 10, 2024